Cancer Biotherapy and Radiopharmaceuticals · 2019 · 19 citations · 26 references
MedicineCancer BiologyOncologyApoptosisChemotherapyMolecular OncologyApoptosis In CancerApoptosis ResistanceCancer ProgressionCervical CancerMalignant NeoplasmsSquamous Cell CarcinomaCancer Cell ApoptosisDual-luciferase AssaysLuciferase Reporter AssaysMicrorna Function In CancerMicrorna-mediated Apoptosis ControlProtein Expression LevelsReporter Gene AssaysTumor Cell Proliferation
Cancer Biotherapy and Radiopharmaceuticals officially retracts the paper entitled, “MiR-181a Promotes Apoptosis and Reduces Cisplatin Resistance by Inhibiting Osteopontin in Cervical Cancer Cells,” by Xiaofei Xu, Xiaofei Jiang, Liping Chen, Yu Zhao, Zhihua Huang, Huifang Zhou, and Mingqing Shi (Cancer Biother Radiopharm. 2019;34(9)559–565; doi: 10.1089/cbr.2019.2858) due to the discovery that the paper was submitted from a paper mill. This is a violation of the journal's standard protocols and is considered an infraction against the rigorous standards of scientific publishing. The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves, and does not tolerate any improprieties.
26
Renhong Huang, Yingjun Quan, Jinhong Chen et al. · Cellular Physiology and Biochemistry · 2017 · 83 citations · Full text
Meng Yang, Xu Zhai, Tingting Ge et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2017 · 60 citations · Full text
Medicine, Cancer Biology, Oncology +17